Physician profile
Gavin Little
NPI 1598792004
$5,503.36
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $1,719 · 2021: $1,744.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $990.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $620.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.93 | 2019-2021 | |
| Lilly USA, LLC | $436.85 | 2019-2021 | |
| Glaxosmithkline, LLC. | $405.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $246.74 | 2019-2021 | |
| Astellas Pharma US INC | $229.17 | 2019-2021 | |
| Novo Nordisk INC | $201.59 | 2019-2021 | |
| Allergan, INC. | $201.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.41 | 2019-2021 | |
| Abbvie INC. | $145.62 | 2021 | |
| Avanir Pharmaceuticals, INC. | $130.88 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $128.72 | 2019-2020 | |
| Amgen INC. | $119.24 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $111.95 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $108.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $95.10 | 2019-2021 | |
| Esperion Therapeutics, INC. | $74.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $61.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $50.99 | 2021 | |
| Lundbeck LLC | $50.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $47.07 | 2021 | |
| Jazz Pharmaceuticals INC. | $46.54 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.81 | 2019-2021 | |
| Amarin Pharma, INC. | $29.66 | 2020 | |
| Sunovion Pharmaceuticals INC. | $28.91 | 2021 | |
| Ge Healthcare | $22.94 | 2020 | |
| Medtronic Minimed, INC. | $21.59 | 2019 | |
| Eisai INC. | $18.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.60 | 2019 | |
| Alkermes, INC. | $12.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.